IL287381B2 - Pharmaceutical preparations of human rpe cells and uses thereof - Google Patents

Pharmaceutical preparations of human rpe cells and uses thereof

Info

Publication number
IL287381B2
IL287381B2 IL287381A IL28738121A IL287381B2 IL 287381 B2 IL287381 B2 IL 287381B2 IL 287381 A IL287381 A IL 287381A IL 28738121 A IL28738121 A IL 28738121A IL 287381 B2 IL287381 B2 IL 287381B2
Authority
IL
Israel
Prior art keywords
pharmaceutical preparations
rpe cells
human rpe
human
cells
Prior art date
Application number
IL287381A
Other languages
English (en)
Hebrew (he)
Other versions
IL287381B1 (en
IL287381A (en
Original Assignee
Astellas Inst For Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47470610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL287381(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Inst For Regenerative Medicine filed Critical Astellas Inst For Regenerative Medicine
Publication of IL287381A publication Critical patent/IL287381A/en
Publication of IL287381B1 publication Critical patent/IL287381B1/en
Publication of IL287381B2 publication Critical patent/IL287381B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mechanical Engineering (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
IL287381A 2011-11-14 2012-11-14 Pharmaceutical preparations of human rpe cells and uses thereof IL287381B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161559521P 2011-11-14 2011-11-14
US201261589741P 2012-01-23 2012-01-23
US201261724047P 2012-11-08 2012-11-08
PCT/US2012/065091 WO2013074681A1 (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human rpe cells and uses thereof

Publications (3)

Publication Number Publication Date
IL287381A IL287381A (en) 2021-12-01
IL287381B1 IL287381B1 (en) 2023-12-01
IL287381B2 true IL287381B2 (en) 2024-04-01

Family

ID=47470610

Family Applications (5)

Application Number Title Priority Date Filing Date
IL287381A IL287381B2 (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human rpe cells and uses thereof
IL320536A IL320536A (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human RPE cells and their use
IL308205A IL308205B2 (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human RPE cells and their use
IL232600A IL232600B (en) 2011-11-14 2014-05-13 Pharmaceutical preparations of human rpe cells and uses thereof
IL273107A IL273107B (en) 2011-11-14 2020-03-05 Pharmaceutical preparations of human rpe cells and their use

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL320536A IL320536A (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human RPE cells and their use
IL308205A IL308205B2 (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human RPE cells and their use
IL232600A IL232600B (en) 2011-11-14 2014-05-13 Pharmaceutical preparations of human rpe cells and uses thereof
IL273107A IL273107B (en) 2011-11-14 2020-03-05 Pharmaceutical preparations of human rpe cells and their use

Country Status (23)

Country Link
US (4) US20130195806A1 (enExample)
EP (2) EP2780022B2 (enExample)
JP (7) JP6506023B2 (enExample)
KR (1) KR102054904B1 (enExample)
CN (2) CN113786417A (enExample)
AU (5) AU2012340020A1 (enExample)
CA (2) CA2855941A1 (enExample)
CY (1) CY1121819T1 (enExample)
DK (1) DK2780022T4 (enExample)
ES (1) ES2734453T3 (enExample)
FI (1) FI2780022T4 (enExample)
GB (1) GB2496969A (enExample)
HK (1) HK1202456A1 (enExample)
HR (1) HRP20191110T1 (enExample)
HU (1) HUE044778T2 (enExample)
IL (5) IL287381B2 (enExample)
LT (1) LT2780022T (enExample)
PL (1) PL2780022T3 (enExample)
PT (1) PT2780022T (enExample)
RS (1) RS59050B1 (enExample)
SI (1) SI2780022T1 (enExample)
TW (5) TWI655286B (enExample)
WO (1) WO2013074681A1 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
CA2937099A1 (en) 2004-01-23 2005-08-04 Astellas Institute For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
EP2209888B1 (en) 2007-10-12 2019-12-04 Astellas Institute for Regenerative Medicine Improved methods of producing rpe cells and compositions of rpe cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
IL281453B (en) 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
US10852069B2 (en) 2010-05-04 2020-12-01 Fractal Heatsink Technologies, LLC System and method for maintaining efficiency of a fractal heat sink
EP3875599B1 (en) 2010-07-23 2024-12-11 Astellas Institute for Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
AU2012314514B2 (en) 2011-09-26 2018-03-15 Qiagen Gmbh Stabilisation and isolation of extracellular nucleic acids
WO2013045458A1 (en) 2011-09-26 2013-04-04 Preanalytix Gmbh Stabilisation and isolation of extracellular nucleic acids
IL287381B2 (en) * 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
JP6608280B2 (ja) 2012-09-25 2019-11-20 キアゲン ゲーエムベーハー 生物学的試料の安定化
DK2951290T3 (en) 2013-02-01 2018-01-22 Us Health PROCEDURE FOR PREPARING RETINAL PIGMENTAL EPIT (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS)
EP2976424B1 (en) 2013-03-18 2018-10-03 Qiagen GmbH Stabilisation of biological samples
US20160281133A1 (en) 2013-03-18 2016-09-29 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
BR112016011096A2 (pt) 2013-11-27 2017-09-19 Kyoto Prefectural Public Univ Corp Aplicação de laminina à cultura de célula endotelial da córnea
AU2014363032A1 (en) 2013-12-11 2016-06-09 Pfizer Limited Method for producing retinal pigment epithelial cells
EP2898896A1 (en) * 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
CN106102766A (zh) * 2014-01-22 2016-11-09 皮埃尔与玛丽·居里大学 - 巴黎第六大学 用于治疗视网膜炎症的试剂
CA2940692C (en) * 2014-03-18 2025-07-08 Qiagen Gmbh STABILIZATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS
WO2015175504A1 (en) * 2014-05-12 2015-11-19 The Johns Hopkins University Differentiation of human pluripotent stem cells into retinal pigment epithelium using hif1 inhibitors
US10457915B2 (en) 2014-05-15 2019-10-29 International Stem Cell Corporation Chemical differentiation of pluripotentstem cells into retinal epithelial cells
WO2015173425A1 (en) 2014-05-16 2015-11-19 Koninklijke Nederlandse Akademie Van Wetenschappen Improved culture method for organoids
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
US20160095307A1 (en) 2014-10-07 2016-04-07 NuTech Medical, Inc. Method and composition for hypothermic storage of placental tissue
EP3207128B1 (en) 2014-10-17 2022-07-27 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
MX387839B (es) * 2014-10-31 2025-03-04 Senju Pharma Co Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea.
JP6770435B2 (ja) * 2014-10-31 2020-10-14 京都府公立大学法人 ラミニンによる網膜および神経の新規治療
EP3233093B1 (en) * 2014-12-18 2022-06-29 Sorbonne Universite Transgenic rpe cells overexpressing otx2 for the treatment of retinal degeneration
AU2015373050B2 (en) 2014-12-30 2022-09-29 Cell Cure Neurosciences Ltd. RPE cell populations and methods of generating same
CA2972700A1 (en) * 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Methods of treating retinal diseases
US20180011092A1 (en) 2014-12-30 2018-01-11 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
EP3869195B1 (en) * 2015-03-23 2024-03-20 Astellas Institute for Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
CN105013010B (zh) * 2015-07-07 2018-01-12 中山大学中山眼科中心 一种辅助iPS‑RPE移植的层粘连蛋白膜
CN108138144A (zh) 2015-08-05 2018-06-08 细胞治疗神经科学有限公司 视网膜色素上皮细胞的制备
KR102411018B1 (ko) 2015-08-18 2022-06-20 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
US11162070B2 (en) * 2015-09-08 2021-11-02 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
JP7166169B2 (ja) 2015-11-20 2022-11-07 キアゲン ゲーエムベーハー 細胞外核酸の滅菌のための滅菌組成物を調製する方法
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
CN106420809B (zh) * 2016-08-31 2017-08-08 浙江济民制药股份有限公司 一种眼科手术灌注液
US12215349B2 (en) * 2016-12-13 2025-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US11076984B2 (en) * 2017-03-13 2021-08-03 Gyroscope Therapeutics Limited Method of performing subretinal drainage and agent delivery
US20200085882A1 (en) * 2017-03-16 2020-03-19 Lineage Cell Therapeutics, Inc. Methods for measuring therapeutic effects of retinal disease therapies
CN110662549A (zh) * 2017-05-01 2020-01-07 路易斯安娜州立大学监测委员会，农业和机械学院 用于治疗眼病的组合物和方法
GB201721615D0 (en) 2017-12-21 2018-02-07 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures
BR112020013238A2 (pt) * 2017-12-29 2020-12-01 Cell Cure Neurosciences Ltd. composição e método para formular células do epitélio pigmentar da retina bem como uso da dita composição para tratar uma condição retiniana
CN112351755A (zh) 2018-02-22 2021-02-09 伊万提斯公司 眼部植入物和输送系统
CA3092588A1 (en) * 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CA3119041A1 (en) * 2018-11-19 2020-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biodegradable tissue replacement implant and its use
GB201819224D0 (en) 2018-11-26 2019-01-09 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatocyte expansion methods
BR112021009913A2 (pt) * 2018-12-05 2021-08-17 Abeona Therapeutics, Inc. vetor viral adeno-associado recombinante para inserção gênica
US12678067B1 (en) 2019-03-20 2026-07-14 Biological Art Group, Inc. Telemetry implants
CN113874494A (zh) * 2019-05-28 2021-12-31 豪夫迈·罗氏有限公司 产生单核细胞祖细胞的方法
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
KR102198942B1 (ko) * 2019-07-02 2021-01-05 의료법인 성광의료재단 Pedf를 발현하거나 모세포에 비하여 pedf를 과발현하도록 유전적으로 조작된 중간엽 줄기세포
WO2021034784A1 (en) 2019-08-16 2021-02-25 Poltorak Technologies, LLC Device and method for medical diagnostics
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
AU2020374884A1 (en) 2019-10-30 2022-06-09 Astellas Institute For Regenerative Medicine Methods for producing retinal pigment epithelium cells
EP4061942A4 (en) * 2019-11-22 2023-12-20 Sigilon Therapeutics, Inc. MONOCLONAL CELL LINES EXPRESSING AN EXOGENEOUS SUBSTANCE AND THEIR USES
IL294874B1 (en) 2020-01-21 2026-06-01 Takeda Pharmaceutical Co Limited Preparations and methods for cryopreservation of cells
AU2021217222A1 (en) * 2020-02-07 2022-09-29 The Trustees Of Columbia University In The City Of New York Reprogramming the metabolome to delay onset or treat neurodegeneration
TW202216158A (zh) * 2020-07-10 2022-05-01 國立研究開發法人理化學研究所 網膜色素上皮細胞之移植用存活促進劑
CN112544612A (zh) * 2020-12-18 2021-03-26 江苏艾尔康生物医药科技有限公司 冻存液及其在rpe细胞冻存中的应用
CN112834411B (zh) * 2021-01-07 2022-05-27 上海交通大学 应用于质谱流式技术的金属纳米探针及制备方法和应用
EP4284415A4 (en) * 2021-01-26 2024-12-11 Sigilon Therapeutics, Inc. BIOCOMPATIBLE DEVICES FOR CELL-BASED THERAPIES AND RELATED METHODS
CN112926116B (zh) * 2021-03-01 2023-02-17 哈尔滨工业大学 一种基于虚拟现实的体育馆火灾疏散行为数据收集系统及其收集方法
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
WO2023149420A1 (ja) * 2022-02-01 2023-08-10 株式会社坪田ラボ 近視を予防または治療するための方法および組成物
CN114561356B (zh) * 2022-03-09 2022-09-13 北京呈诺医学科技有限公司 影响细胞因子分泌的方法及应用
CN118871141A (zh) * 2022-03-16 2024-10-29 住友制药株式会社 移植用介质
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
EP4698206A1 (fr) * 2023-04-21 2026-02-25 PulseSight Therapeutics Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
EP4704870A1 (en) * 2023-05-05 2026-03-11 The Regents of University of California Retinal pigment epithelium cell therapy
CN117625536B (zh) * 2024-01-26 2024-04-30 中国人民解放军总医院第三医学中心 一种人视网膜色素上皮细胞的纯化、培养方法
JP2025139102A (ja) 2024-03-12 2025-09-26 株式会社サトー プリンタ、プログラム、プリンタの情報処理方法
WO2026110810A1 (ja) * 2024-11-21 2026-05-28 セントラル硝子株式会社 凍結解凍した移植用三次元細胞培養体を浸すための溶液、溶液製造方法、移植用三次元細胞培養体の凍結解凍物、凍結解凍物を得る製造方法、溶液の使用方法、および、移植用キット

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063005A2 (en) * 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138205A (en) 1975-12-15 1979-02-06 Hydro Pulse Corporation Movable stator walls permitting access to tubing in peristaltic pump
US5610753A (en) 1991-12-12 1997-03-11 Eastman Kodak Company Optical design of laser scanner to reduce thermal sensitivity
GB9608145D0 (en) * 1996-04-19 1996-06-26 British Tech Group Wound healing
US20040086494A1 (en) * 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
US5998423A (en) 1996-10-08 1999-12-07 Therasys, Inc. Methods for modulating melanin production
US6440933B1 (en) 1997-09-10 2002-08-27 University Of Florida Compounds and method for the prevention and treatment of diabetic retinopathy
JP2002500202A (ja) * 1998-01-02 2002-01-08 タイタン ファーマシューティカルズ， インコーポレイテッド 免疫優位部位の生成のための色素性網膜上皮細胞の使用
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6576422B1 (en) * 2000-10-17 2003-06-10 Rohm And Haas Company Method for identifying products employing gene expression
US6699493B2 (en) 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
WO2002087530A1 (en) * 2001-04-27 2002-11-07 The General Hospital Corporation Tyrosinase assay
EP1427835B1 (en) * 2001-08-08 2016-01-20 The Trustees of the University of Pennsylvania Method for purification of viral vectors having proteins which bind sialic acid
US20030232430A1 (en) 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
WO2003060083A2 (en) 2002-01-15 2003-07-24 Advanced Cell Technology, Inc. Cloning b and t lymphocytes
US20040091936A1 (en) 2002-05-24 2004-05-13 Michael West Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank
US7803750B2 (en) 2002-07-29 2010-09-28 Duke University Method of modulating melanin production
US7794704B2 (en) * 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
CA2937099A1 (en) * 2004-01-23 2005-08-04 Astellas Institute For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
US7309487B2 (en) * 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
EP1812554A4 (en) 2004-11-04 2008-10-08 Advanced Cell Tech Inc DERIVATION OF EMBRYONAL STEM CELLS
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
ZA200901914B (en) * 2006-09-22 2010-06-30 Riken Stem cell culture medium and method
EP2209888B1 (en) * 2007-10-12 2019-12-04 Astellas Institute for Regenerative Medicine Improved methods of producing rpe cells and compositions of rpe cells
GB0806746D0 (en) 2008-04-14 2008-05-14 Ucl Business Plc Membrane
BRPI0910575A2 (pt) * 2008-04-18 2017-06-06 Arizona Board Of Regents A Body Corp Of The State Of Arizona Acting For And Behalf Of The Univ Of Ar métodos para tratar degeneração macular relacionada com a idade, para limitar desenvolvimento de degeneração macular relacionada com a idade, e para identificar compostos para tratar degeneração macular relacionada com a idade, e, composição
EP3875599B1 (en) * 2010-07-23 2024-12-11 Astellas Institute for Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
CA2831609C (en) 2011-03-30 2019-06-11 Cellular Dynamics International, Inc. Priming of pluripotent stem cells for neural differentiation
EP2702135B1 (en) * 2011-04-29 2019-04-17 University of Southern California Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate
IL287381B2 (en) 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
PL3189135T3 (pl) * 2014-09-05 2021-12-20 Astellas Institute For Regenerative Medicine Komórki zwojowe siatkówki i ich progenitory

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063005A2 (en) * 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LU FAN ET AL,, EXPRESSION OF MELANIN-RELATED GENES IN CULTURED ADULT HUMAN RETINAL PIGMENT EPITHELIUM AND UVEAL MELANOMA CELLS, 3 November 2007 (2007-11-03) *

Also Published As

Publication number Publication date
TW202120107A (zh) 2021-06-01
CA3178098A1 (en) 2013-05-23
US20250134932A1 (en) 2025-05-01
IL273107A (en) 2020-04-30
JP6506023B2 (ja) 2019-04-24
JP7081016B2 (ja) 2022-06-06
WO2013074681A1 (en) 2013-05-23
IL232600A0 (en) 2014-06-30
JP2022130370A (ja) 2022-09-06
TW202317157A (zh) 2023-05-01
LT2780022T (lt) 2019-07-10
PT2780022T (pt) 2019-07-16
AU2012340020A1 (en) 2014-07-03
EP2780022A4 (en) 2015-08-05
GB2496969A (en) 2013-05-29
AU2017225146B2 (en) 2019-01-17
JP2025161815A (ja) 2025-10-24
IL320536A (en) 2025-06-01
CY1121819T1 (el) 2020-07-31
AU2019201201B2 (en) 2021-04-08
AU2025201277A1 (en) 2025-03-13
HUE044778T2 (hu) 2019-11-28
AU2021204719B2 (en) 2024-11-21
HRP20191110T1 (hr) 2019-09-20
IL308205B1 (en) 2025-06-01
JP7716463B2 (ja) 2025-07-31
AU2017225146C1 (en) 2019-08-22
JP6563996B2 (ja) 2019-08-21
JP7404441B2 (ja) 2023-12-25
US20150366915A1 (en) 2015-12-24
CN104080464A (zh) 2014-10-01
DK2780022T3 (da) 2019-07-15
HK1202456A1 (en) 2015-10-02
RS59050B1 (sr) 2019-08-30
JP2024037864A (ja) 2024-03-19
PL2780022T3 (pl) 2019-11-29
FI2780022T4 (fi) 2023-07-06
TWI842079B (zh) 2024-05-11
JP6899865B2 (ja) 2021-07-07
KR102054904B1 (ko) 2019-12-11
AU2017225146A1 (en) 2017-10-05
IL308205B2 (en) 2025-10-01
EP2780022B2 (en) 2022-09-07
TWI785403B (zh) 2022-12-01
IL287381B1 (en) 2023-12-01
TWI719277B (zh) 2021-02-21
TW201333200A (zh) 2013-08-16
JP2018048144A (ja) 2018-03-29
KR20140096368A (ko) 2014-08-05
IL232600B (en) 2020-03-31
EP2780022A1 (en) 2014-09-24
TWI655286B (zh) 2019-04-01
JP2021113193A (ja) 2021-08-05
AU2021204719A1 (en) 2021-08-05
SI2780022T1 (sl) 2019-09-30
WO2013074681A9 (en) 2013-11-28
IL308205A (en) 2024-01-01
ES2734453T3 (es) 2019-12-10
JP2019189614A (ja) 2019-10-31
US20130195806A1 (en) 2013-08-01
CN113786417A (zh) 2021-12-14
DK2780022T4 (da) 2024-09-09
EP2780022B1 (en) 2019-06-05
IL273107B (en) 2021-12-01
US20200405767A1 (en) 2020-12-31
AU2019201201A1 (en) 2019-03-14
TW202434266A (zh) 2024-09-01
GB201220511D0 (en) 2012-12-26
IL287381A (en) 2021-12-01
JP2014533289A (ja) 2014-12-11
CA2855941A1 (en) 2013-05-23
TW201828960A (zh) 2018-08-16
EP3563860A1 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
AU2016204322A1 (en) N-arylamidine-substituted trifluoroethyl sulfide derivatives as acaricides and insecticides
MX386924B (es) Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades.
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
DOP2014000043A (es) Pirimidinas anilladas sustituidas y uso de las mismas
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
MY177242A (en) Imidazopyrrolidinone compounds
DK3045456T3 (da) Bicyklisk substituerede uraciler og anvendelse heraf
MX2010010505A (es) Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
HUE044778T2 (hu) Humán RPE sejt gyógyászati készítmények és alkalmazásaik
EP2841107A4 (en) CYTOTOXIC ACTIVITIES DISPOSED OF HIV RELEASING MOLECULES (CDM-HS), CYTOTOXIC EFFECT AGAINST HUMAN IMMUNE WEAKAGE VIRUS AND METHOD OF USE
PH12018500368A1 (en) Preparations containing amorphous emodepside
EP2906044A4 (en) NOVEL BREVIBACILLUS LATEROSPORUS TRIBES AS AN ORGANIC COMBATIVE AGAINST PLANT PENALTIES, IN PARTICULAR LEPIDOPTERA AND DIPTERA
BRPI1012666B8 (pt) cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
UY31133A1 (es) "oxazolidinonas sustituidas y su uso"
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
UY29189A1 (es) Nonadepsipeptidos acilados ii
HK1199201A1 (en) Antimicrobial peptides for treatment of infectious diseases
BR112014016804A2 (pt) composições, métodos de uso e métodos de tratamento
UA117563C2 (uk) Композиція для лікування або профілактики хвороби, асоційованої з інфекцією впл
BR112014005583A2 (pt) 4,5,6,7-tetra-hidro-1h-pirazolo[4,3-c]piridinas substituídas com indanila, seu uso como medicamento, e preparações farmacêuticas que as contêm
CL2012003434A1 (es) Composicion dermatologica que comprende una combinacion de: 0,1-1% de oxido de cobre; 0,1-1% de oxido de zinc; 0,1-2% de extracto de calendula ( calenduls spp) y entre 0,1-2% de extracto de matico ( buddleja globosa); uso en el tratamiento y prevencion de afecciones en la pie.
CY1116210T1 (el) Χρηση νιφουρατελης για τη θεραπευτικη αγωγη μολυνσεων προκαλουμενων απο ειδος clostridium